BIOGEN INC.

BIIB

BIOGEN INC.

BIIB

Insider Sentiment (TTM):

Last Purchase:2026-02-12Last Sale:2026-02-09Shares Purchased (TTM):3Shares Sold (TTM):3,925

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:127,220,725Shares Outstanding:147,200,000Institutional Ownership Pct.:86.43%

Earnings Market Reaction:

Filing Date:2026-04-29Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in Biological Products, (No Diagnostic Substances)

AMGN GILD SCLX MRNA RVMD NBIX

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Nonrelated Party	1,369	-	-250	21	1,603	-	-91	23	1,605	-	96	1,686
Related Party	1,369	-	-250	21	1,603	-	-91	23	1,605	-	96	1,686
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	3,383	3,009	3,863	2,759	2,598	2,375	1,699	1,909	1,074	1,050	2,288	2,618
Available For Sale Securities Debt Securities Curr…	900	807	98	-	-	0	-	-	-	0	0	3,461
Accounts Receivable Net Current	-	1,342	-	-	-	1,405	-	-	-	1,664	-	-
Inventory Net	1,949	2,168	2,209	2,274	2,274	2,461	2,469	2,506	2,517	2,527	2,982	1,334
Other Assets Current	1,168	1,123	917	851	757	753	674	615	1,165	1,182	974	896
Assets Current	9,190	8,974	8,937	7,968	7,626	7,457	6,831	7,109	6,756	6,859	8,454	10,432
Available For Sale Securities Debt Securities Nonc…	466	432	-	-	-	0	-	-	-	0	0	1,208
Property Plant And Equipment Net	3,018	3,055	3,076	3,099	3,132	3,181	3,211	3,249	3,275	3,310	3,302	3,307
Operating Lease Right Of Use Asset	251	265	331	335	346	356	380	389	428	420	461	367
Intangible Assets Net Excluding Goodwill	9,054	9,179	9,332	9,468	9,585	9,691	9,806	8,233	8,285	8,363	7,345	1,776
Goodwill	6,489	6,491	6,491	6,493	6,477	6,479	6,486	6,227	6,227	6,219	6,808	5,754
Deferred Income Tax Assets Net	238	293	312	331	308	324	969	915	898	929	1,070	1,208
Other Assets Noncurrent	778	751	730	638	559	561	631	682	698	745	755	1,105
Assets	29,483	29,440	29,208	28,330	28,033	28,049	28,313	26,804	26,568	26,845	28,193	25,157
Liabilities And Stockhold…
Liabilities Current
Notes Payable Current	-	-	0	0	1,749	-	1,748	0	250	-	500	-
Debt Current	-	0	-	-	-	1,749	-	-	-	150	-	-
Taxes Payable Current	94	115	103	115	626	548	499	282	231	257	244	260
Accounts Payable Current	359	432	413	408	392	424	423	355	387	403	440	445
Other Liabilities Current	2,547	2,803	2,774	2,661	2,531	2,808	2,755	2,472	2,355	2,624	3,838	2,481
Liabilities Current	2,999	3,349	3,290	3,184	5,297	5,529	5,425	3,108	3,223	3,434	5,022	3,187
Long Term Debt	6,289	6,287	6,285	6,284	4,549	4,547	4,546	6,292	6,290	6,788	6,786	6,285
Deferred Income Tax Liabilities Net	484	508	358	118	133	191	882	591	658	642	728	144
Operating Lease Liability Noncurrent	273	290	305	311	323	335	357	368	407	400	429	304
Other Liabilities Noncurrent	787	749	762	800	752	732	744	557	777	781	748	777
Liabilities	10,831	11,183	11,000	10,696	11,054	11,333	11,954	10,915	11,355	12,045	13,714	10,696
Stockholders Equity Inclu…
Stockholders Equity
Preferred Stock Value Outstanding	-	0	-	-	-	0	-	-	-	0	-	-
Common Stock Value Outstanding	-	0	-	-	-	0	-	-	-	0	-	-
Preferred Stock Value	0	-	0	0	0	-	0	0	0	-	0	0
Common Stock Value	0	-	0	0	0	-	0	0	0	-	0	0
Additional Paid In Capital	897	863	798	714	630	569	489	408	330	303	242	171
Accumulated Other Comprehensive Income Loss Net Of…	-140	-182	-215	-238	-175	-136	-146	-146	-161	-154	-159	-173
Retained Earnings Accumulated Deficit	20,872	20,553	20,602	20,135	19,500	19,260	18,993	18,605	18,021	17,628	17,378	17,446
Treasury Stock Value	-2,977	-2,977	-2,977	-2,977	-2,977	-2,977	-2,977	-2,977	-2,977	-2,977	-2,977	-2,977
Stockholders Equity	18,652	18,257	18,208	17,634	16,979	16,716	16,359	15,889	15,213	14,799	14,480	14,461
Liabilities And Stockholders Equity	29,483	29,440	29,208	28,330	28,033	28,049	28,313	26,804	26,568	26,845	28,193	25,157
Allowance For Doubtful Accounts Receivable Current	3	3	2	2	2	2	2	2	2	2	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	0	-4	-6
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	-	-
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	-	-
Treasury Stock Common Shares	-	24	-	-	-	24	-	-	-	24	-	-

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-0.32%	1.13%	5.97%	-	-	-	-	-	-	-	-	-
2025	4.04%	5.05%	3.36%	8.84%	11.33%	11.72%	17.17%	16.84%	9.90%	-4.65%	-8.62%	-8.35%
2024	14.15%	14.70%	13.90%	-2.71%	-5.38%	-9.75%	-12.85%	-19.16%	-22.43%	12.70%	-7.83%	-7.42%
2023	-	-	-	-3.39%	-5.74%	-2.98%	1.27%	11.69%	5.67%	1.13%	-7.64%	-1.46%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 50+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 50+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	3.06	2.68	2.72	2.50	1.44	1.35	1.26	2.29	2.10	2.00	1.68	3.27
Quick Ratio	2.41	2.03	2.04	1.79	1.01	0.90	0.80	1.48	1.32	1.26	1.09	2.86
Working Capital	6.19B	5.62B	5.65B	4.78B	2.33B	1.93B	1.41B	4.00B	3.53B	3.43B	3.43B	7.25B
Leverage & Debt
Debt to Equity	0.58	0.61	0.60	0.61	0.65	0.68	0.73	0.69	0.75	0.81	0.95	0.74
Debt Ratio	0.37	0.38	0.38	0.38	0.39	0.40	0.42	0.41	0.43	0.45	0.49	0.43
Efficiency & Turnover
Asset Turnover TTM	0.35	0.34	0.35	0.36	0.36	0.35	0.34	0.37	0.38	0.38	0.38	0.40
Days Sales Outstanding TTM	-	50.69	-	-	-	57.88	-	-	-	62.51	-	-
Receivables Turnover TTM	-	7.20	-	-	-	6.31	-	-	-	5.84	-	-
Per Share Metrics
Diluted EPS TTM	9.24	8.79	10.93	10.43	10.09	11.19	11.05	7.93	8.00	7.97	9.52	17.74
Free Cash Flow Per Share TTM	16.46	14.00	15.72	13.51	16.68	18.69	13.37	10.75	9.56	8.78	7.33	7.91
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	75.49%	75.69%	75.24%	75.43%	75.58%	76.12%	75.59%	75.54%	75.03%	74.24%	75.12%	76.98%
Operating Profit Margin TTM	16.33%	15.74%	18.92%	17.98%	17.85%	19.70%	19.84%	13.58%	13.69%	13.18%	16.10%	31.30%
Net Profit Margin TTM	13.81%	13.07%	15.98%	15.31%	15.07%	16.87%	16.80%	11.96%	12.07%	11.81%	13.79%	25.88%
Growth Metrics
Net Revenue Growth (1Y)	1.23%	2.22%	4.77%	3.36%	1.59%	-1.62%	-3.86%	-3.00%	-4.37%	-3.32%	-3.57%	-6.23%
Net Income Growth (1Y)	-7.26%	-20.79%	-0.32%	32.29%	26.80%	40.57%	17.10%	-55.18%	-61.70%	-60.79%	-52.18%	25.00%
EPS Growth (1Y)	-7.95%	-21.27%	-0.93%	31.48%	26.02%	39.70%	16.38%	-55.45%	-61.91%	-60.63%	-52.31%	26.04%
Valuation Metrics
P/E TTM	19.67	19.94	12.77	12.02	13.51	13.64	17.50	29.18	26.84	32.25	27.01	15.97
P/B TTM	1.45	1.41	1.13	1.04	1.18	1.33	1.73	2.12	2.06	2.53	2.57	2.85
P/S TTM	2.72	2.61	2.04	1.84	2.04	2.30	2.94	3.49	3.24	3.81	3.72	4.13
Market Cap	26.99B	25.78B	20.54B	18.40B	19.99B	22.27B	28.24B	33.75B	31.31B	37.44B	37.22B	41.22B
Enterprise Value	29.89B	29.06B	22.96B	21.92B	23.69B	26.19B	32.84B	38.14B	36.78B	43.33B	42.21B	44.88B
Calculated Values
Free Cash Flow TTM	2.42B	2.05B	2.30B	1.98B	2.44B	2.72B	1.95B	1.57B	1.39B	1.27B	1.06B	1.15B
Net Debt	2.91B	3.28B	2.42B	3.52B	3.70B	3.92B	4.59B	4.38B	5.47B	5.89B	5.00B	3.67B
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-02-12Purchase

Owner: Murphy, Nicole

Title: Head of Pharm Ops and Tech

Shares: 3

Price/Share: $195.04

Value: $585.12

Shares Owned: 19,611

Relationship: Officer

Ownership: Direct

2026-02-09Sale

Owner: Singhal, Priya

Title: Head of Development

Shares: 2,660

Price/Share: $199.83

Value: $531,547.80

Shares Owned: 8,043

Relationship: Officer

Ownership: Direct

2026-02-02Sale

Owner: Singhal, Priya

Title: Head of Development

Shares: 748

Price/Share: $179.30

Value: $134,116.40

Shares Owned: 6,271

Relationship: Officer

Ownership: Direct

2025-09-02Sale

Owner: Singhal, Priya

Title: Head of Development

Shares: 517

Price/Share: $133.55

Value: $69,045.35

Shares Owned: 5,772

Relationship: Officer

Ownership: Direct

2025-07-08Sale

Owner: Izzar, Rachid

Title: Head of Global Product Strat.

Shares: 2,223

Price/Share: $135.00

Value: $300,105.00

Shares Owned: 6,330

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-02-12	Murphy, Nicole	Officer	Head of Pharm Ops and Tech	Direct	Purchase	3	195.04	$585.12	19,611	4
2026-02-09	Singhal, Priya	Officer	Head of Development	Direct	Sale	2,660	199.83	$531,547.80	8,043	4
2026-02-02	Singhal, Priya	Officer	Head of Development	Direct	Sale	748	179.30	$134,116.40	6,271	4
2025-09-02	Singhal, Priya	Officer	Head of Development	Direct	Sale	517	133.55	$69,045.35	5,772	4
2025-07-08	Izzar, Rachid	Officer	Head of Global Product Strat.	Direct	Sale	2,223	135.00	$300,105.00	6,330	4
2025-05-19	Singhal, Priya	Officer	Head of Development	Direct	Sale	3,806	126.25	$480,507.50	5,427	4
2025-05-02	Dorsa, Caroline	Director	-	Direct	Purchase	1,235	122.72	$151,559.20	27,842	4
2025-03-07	Sherwin, Stephen A	Director	-	Direct	Sale	8,760	150.02	$1,314,175.20	11,318	4
2024-12-09	Singhal, Priya	Officer	Head of Development	Direct	Sale	110	157.21	$17,293.10	5,426	4
2024-09-03	Singhal, Priya	Officer	Head of Development	Direct	Sale	431	204.22	$88,018.82	5,316	4
2024-04-02	Singhal, Priya	Officer	Head of Development	Direct	Sale	93	213.09	$19,817.37	4,886	4
2024-02-22	Singhal, Priya	Officer	Head of Development	Direct	Sale	262	221.23	$57,962.26	4,886	4
2024-02-16	Singhal, Priya	Officer	Head of Development	Direct	Sale	108	221.49	$23,920.92	5,148	4
2024-02-15	Rowinsky, Eric K	Director	-	Direct	Purchase	455	222.54	$101,255.70	20,629	4
2024-02-12	Singhal, Priya	Officer	Head of Development	Direct	Sale	419	239.45	$100,329.55	4,516	4
2024-02-02	Singhal, Priya	Officer	Head of Development	Direct	Sale	634	245.93	$155,919.62	4,097	4
2023-12-11	Singhal, Priya	Officer	Head of Development	Direct	Sale	110	248.00	$27,280.00	3,464	4
2023-09-05	Singhal, Priya	Officer	Head of Development	Direct	Sale	431	269.43	$116,124.33	3,354	4
2023-07-03	Singhal, Priya	Officer	Head of Development	Direct	Sale	81	282.87	$22,912.47	2,924	4
2023-04-28	Gregory, Ginger	Officer	EVP, Human Resources	Direct	Sale	2,681	300.00	$804,300.00	8,483	4
2023-04-04	Singhal, Priya	Officer	Head of Development	Direct	Sale	91	277.11	$25,217.01	2,843	4
2023-03-28	Singhal, Priya	Officer	Head of Development	Direct	Sale	568	270.06	$153,394.08	2,842	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

86.43%

Inst. Shares: 127,220,725

Shares Outstanding: 147,200,000

2025-12-31

89.99%

Inst. Shares: 131,838,558

Shares Outstanding: 146,500,000

2025-09-30

85.37%

Inst. Shares: 125,152,613

Shares Outstanding: 146,600,000

2025-06-30

84.11%

Inst. Shares: 123,222,612

Shares Outstanding: 146,500,000

2025-03-31

80.71%

Inst. Shares: 117,914,615

Shares Outstanding: 146,100,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	127,220,725	147,200,000	86.43%
2025-12-31	131,838,558	146,500,000	89.99%
2025-09-30	125,152,613	146,600,000	85.37%
2025-06-30	123,222,612	146,500,000	84.11%
2025-03-31	117,914,615	146,100,000	80.71%
2024-12-31	120,704,767	145,600,000	82.90%
2024-09-30	115,145,924	145,700,000	79.03%
2024-06-30	115,162,258	145,600,000	79.09%
2024-03-31	112,558,305	145,200,000	77.52%
2023-12-31	113,871,079	144,700,000	78.69%
2023-09-30	108,616,951	144,800,000	75.01%
2023-06-30	111,781,886	144,700,000	77.25%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

BIOGEN INC. (BIIB) — SEC Financial Statements & Analysis

BIOGEN INC. (BIIB) is a biological products, (no diagnostic substances) company, incorporated in DE. BIOGEN INC. trades on BIIB: Nasdaq as: BIIB. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), BIOGEN INC. reported a 1.23% year-over-year revenue growth, a Gross Profit Margin of 75.49% (TTM), a Debt-to-Equity ratio of 0.58x, a Price-to-Sales (P/S) ratio of 2.72x (TTM), a Price-to-Book (P/B) ratio of 1.45 (TTM), at a market cap of $26.99B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 1.23%
Gross Profit Margin TTM: 75.49%
Debt To Equity: 0.58x
P/S TTM: 2.72x
P/B TTM: 1.45
Market Cap: $26.99B

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is BIOGEN INC. in?

BIOGEN INC. (BIIB) operates in the Biological Products, (No Diagnostic Substances) industry.

What is BIIB's market cap?

BIOGEN INC. (BIIB) has a market capitalization of $26.99B as of 2026-03-31.

What is BIIB's P/E ratio?

BIOGEN INC. (BIIB)'s trailing twelve month P/E ratio is 19.67x as of 2026-03-31.

What exchange does BIIB trade on?

BIOGEN INC. (BIIB) trades on the BIIB: Nasdaq.

Where is BIOGEN INC. incorporated?

BIOGEN INC. is incorporated in DE.

BIOGEN INC. (BIIB) — SEC Financial Statements & Analysis

Frequently Asked Questions

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.